This decision analytical model study evaluates the effects of relabeling grade group 1 prostate cancer on prostate cancer mortality in the US.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Race, Secondary Treatment, and Survival in Localized Prostate Cancer | 0 | 5.24 | 21-07-2026 |
| 2 | Long-Term Adverse Effects and Complications After Prostate Cancer Treatment | 0 | 9.73 | 01-12-2024 |
| 3 | Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer | 0 | 5 | 18-06-2026 |
| 4 | Racial Variations in Secondary Treatment and Survival in Prostate Cancer | 0 | 7.35 | 21-07-2026 |
| 5 | PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review | 0 | 8.34 | 16-07-2026 |
| 6 | Circulating Tumor DNA in Early Breast Cancer | 0 | 9.02 | 01-07-2026 |
| 7 | PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression | 0 | 15.58 | 01-07-2026 |
| 8 | Tissue-Free vs Tumor-Informed Circulating Tumor DNA Assays in Early Triple Negative Breast Cancer | 0 | 12.99 | 13-08-2026 |
| 9 | Individualized Stereotactic Ablative Radiotherapy for Lung Tumors | 0 | 6.6 | 01-11-2023 |